Literature DB >> 12101178

The glycan domain of thrombopoietin (TPO) acts in trans to enhance secretion of the hormone and other cytokines.

Hannah M Linden1, Kenneth Kaushansky.   

Abstract

Thrombopoietin (TPO), the primary regulator of platelet production, is composed of an amino-terminal 152 amino acids, sufficient for activity, and a carboxyl-terminal region rich in carbohydrates (183 residues) that enhances secretion of the molecule. Full-length TPO is secreted at levels 10-20-fold greater than truncated TPO. By introducing into mammalian cells a novel cDNA encoding the TPO secretory leader linked to its carboxyl-terminal domain (TPO glycan domain (TGD)), we tested whether TGD could function in trans to enhance secretion of TPO. The artificial TGD was secreted, inactive in proliferation assays, and did not inhibit TPO activity. However, when co-transfected with a cDNA encoding truncated TPO, TGD enhanced secretion 4-fold, measured by specific bioassay and immunoassay. TGD also enhanced secretion of granulocyte monocyte colony-stimulating factor and stem cell factor but did not affect the production of erythropoietin, interleukin-3, growth hormone, or of full-length TPO. To localize TGD function, we added an endoplasmic reticulum (ER) retention signal to TGD and, separately, deleted the secretory leader. Deletion of the secretory leader attenuated the secretory function of TGD, whereas addition of the ER retention signal did not alter its function. To investigate the physiologic role of TGD in folding and proteasomal protection, we tested full-length and truncated TPO in assays of protein refolding, and we examined protein stability in the presence of proteasome inhibitors. We found that truncated TGD re-folds readily and that proteasome-mediated degradation contributes to the poor secretion of truncated TPO. We conclude that TGD enhances secretion of TPO and can additionally function as an inter-molecular chaperone, in part because of its ability to prevent degradation of the hormone. The cellular location of TGD action is likely to be within the ER or earlier in the secretory pathway.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12101178     DOI: 10.1074/jbc.M201297200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  4 in total

1.  Bone marrow failure unresponsive to bone marrow transplant is caused by mutations in thrombopoietin.

Authors:  Aaron Seo; Miri Ben-Harosh; Mehtap Sirin; Jerry Stein; Orly Dgany; Joseph Kaplelushnik; Manfred Hoenig; Ulrich Pannicke; Myriam Lorenz; Klaus Schwarz; Clemens Stockklausner; Tom Walsh; Suleyman Gulsuner; Ming K Lee; Anoop Sendamarai; Marilyn Sanchez-Bonilla; Mary-Claire King; Holger Cario; Andreas E Kulozik; Klaus-Michael Debatin; Ansgar Schulz; Hannah Tamary; Akiko Shimamura
Journal:  Blood       Date:  2017-05-30       Impact factor: 22.113

2.  Monoallelic loss-of-function THPO variants cause heritable thrombocytopenia.

Authors:  Naomi Cornish; M Riyaad Aungraheeta; Lucy FitzGibbon; Kate Burley; Dominic Alibhai; Janine Collins; Daniel Greene; Kate Downes; Sarah K Westbury; Ernest Turro; Andrew D Mumford
Journal:  Blood Adv       Date:  2020-03-10

3.  Quantifying single-cell secretion in real time using resonant hyperspectral imaging.

Authors:  José Juan-Colás; Ian S Hitchcock; Mark Coles; Steven Johnson; Thomas F Krauss
Journal:  Proc Natl Acad Sci U S A       Date:  2018-12-10       Impact factor: 11.205

Review 4.  The thrombopoietin receptor: revisiting the master regulator of platelet production.

Authors:  Ian S Hitchcock; Maximillian Hafer; Veena Sangkhae; Julie A Tucker
Journal:  Platelets       Date:  2021-06-07       Impact factor: 3.862

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.